Kevin Koch is CEO & President at Edgewise Therapeutics, Inc. (EWTX). They have made 6 open-market trades across 2 companies since 2006, most recently 2026-08-12.
CIK 0001185829
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ARRY | 786,917 | $2.7M |
| EWTX | 52,488 | $2.0M |
| Total | $4.6M |
Shares reported on the most recent Form 4, priced at the 2026-08-14 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| EWTX | SELL | 2026-08-12 | 2026-08-14 | $43.68 | $785K | +1.7% | +2.0% | — |
| EWTX | SELL | 2025-08-12 | 2025-08-14 | $13.39 | $213K | +4.4% | -2.0% | +51.4% |
| EWTX | SELL | 2025-05-02 | 2025-05-07 | $16.45 | $141K | +1.9% | +5.0% | -5.3% |
| EWTX | SELL · 10b5-1 | 2025-03-07 | 2025-03-11 | $30.00 | $3K | -14.2% | -58.0% | -44.6% |
| EWTX | SELL · 10b5-1 | 2025-02-05 | 2025-02-07 | $30.08 | $547K | +2.6% | +4.2% | -44.3% |
| EWTX | SELL | 2024-05-02 | 2024-05-03 | $18.91 | $119K | -8.4% | -9.8% | -13.2% |
| EWTX | SELL | 2023-05-02 | 2023-05-03 | $8.90 | $29K | -2.1% | +5.3% | -23.5% |
| ARRY | SELL · 10b5-1 | 2007-02-05 | 2007-02-07 | $14.06 | $281K | +33.9% | +23.6% | +23.6% |
| ARRY | SELL | 2007-01-19 | 2007-01-19 | $14.00 | $377K | +33.9% | +23.6% | +23.6% |
| ARRY | SELL · 10b5-1 | 2006-02-17 | 2006-02-22 | $9.38 | $188K | +33.9% | +23.6% | +23.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.